Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation

Haematologica. 2007 Mar;92(3):414-7. doi: 10.3324/haematol.10570.

Abstract

In this study, we tested the efficacy and safety of donor lymphocyte infusion (DLI) with granulocyte colony-stimulating factor (G-CSF) priming in patients who relapsed after haploidentical hematopoietic stem cell transplantation (HSCT). Twenty patients received DLI at a median of 177 days after HSCT. Eight patients survived in complete remission for a median of 1118 days. The 2-year probability of leukemia-free survival was 40%. Acute graft-versus-host disease (GVHD) grade 3-4 occurred in six patients after DLI. GVHD prophylaxis reduced the incidence of acute GVHD. Our primary data showed that G-CSF-primed DLI with GVHD prophylaxis was a potentially effective therapeutic option for patients who relapsed after haploidentical HSCT.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Child
  • Combined Modality Therapy
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Disease-Free Survival
  • Etoposide / therapeutic use
  • Female
  • Graft vs Host Disease / epidemiology
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / prevention & control
  • Graft vs Leukemia Effect*
  • HLA Antigens / genetics
  • Haplotypes / genetics
  • Histocompatibility
  • Humans
  • Imatinib Mesylate
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Kaplan-Meier Estimate
  • Leukemia / drug therapy
  • Leukemia / surgery*
  • Lymphocyte Transfusion* / adverse effects
  • Male
  • Methotrexate / therapeutic use
  • Mitoxantrone / therapeutic use
  • Pancytopenia / epidemiology
  • Pancytopenia / etiology
  • Peripheral Blood Stem Cell Transplantation*
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Recurrence
  • Remission Induction
  • Salvage Therapy*
  • Tissue Donors*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • HLA Antigens
  • Immunosuppressive Agents
  • Piperazines
  • Pyrimidines
  • Cytarabine
  • Etoposide
  • Imatinib Mesylate
  • Mitoxantrone
  • Methotrexate
  • Daunorubicin